What have we learnt thus far from mice with disrupted P-glycoprotein genes?
- 30 June 1996
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (6), 985-990
- https://doi.org/10.1016/0959-8049(96)00063-9
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- PROTEIN PRENYLATION: Molecular Mechanisms and Functional ConsequencesAnnual Review of Biochemistry, 1996
- Characterization of Prenylcysteines That Interact with P-glycoprotein and Inhibit Drug Transport in Tumor CellsPublished by Elsevier ,1995
- Multidrug resistance and the role of P-glycoprotein knockout miceEuropean Journal Of Cancer, 1995
- MDR Expression in Normal Tissues: Pharmocologic Implication for the Clinical Use of P-Glycoprotein InhibitorsHematology/Oncology Clinics of North America, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994
- P-glycoprotein expression and function in circulating blood cells from normal volunteersBlood, 1994
- Clinical relevance of P-glycoprotein expression in haematological malignanciesLeukemia Research, 1994
- Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammalsPharmacology & Therapeutics, 1993
- Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cellsCancer Immunology, Immunotherapy, 1993
- Multidrug resistance activity in human lymphocytesHuman Immunology, 1991